Healthcare - Biotechnology - NASDAQ - IL
$ 2.23
1.36 %
$ 156 M
Market Cap
-5.57
P/E
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.[ Read More ]
The intrinsic value of one DRTS stock under the base case scenario is HIDDEN Compared to the current market price of 2.23 USD, Alpha Tau Medical Ltd. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart DRTS
FINANCIALS
0
REVENUE
35.7 M
OPERATING INCOME
-29.2 M
NET INCOME
-18 M
OPERATING CASH FLOW
18.7 M
INVESTING CASH FLOW
5.3 M
FINANCING CASH FLOW
0
REVENUE
-9.05 M
OPERATING INCOME
-7.37 M
NET INCOME
0
OPERATING CASH FLOW
0
INVESTING CASH FLOW
0
FINANCING CASH FLOW
Balance Sheet Decomposition
Alpha Tau Medical Ltd.
| Current Assets | 85.8 M |
| Cash & Short-Term Investments | 81.8 M |
| Receivables | 0 |
| Other Current Assets | 3.97 M |
| Non-Current Assets | 21.6 M |
| Long-Term Investments | 0 |
| PP&E | 21.2 M |
| Other Non-Current Assets | 471 K |
| Current Liabilities | 7.1 M |
| Accounts Payable | 2.57 M |
| Short-Term Debt | 1.06 M |
| Other Current Liabilities | 3.47 M |
| Non-Current Liabilities | 15.8 M |
| Long-Term Debt | 12.2 M |
| Other Non-Current Liabilities | 3.6 M |
EFFICIENCY
Earnings Waterfall
Alpha Tau Medical Ltd.
| Revenue | 0 |
| Cost Of Revenue | 1.07 M |
| Gross Profit | -1.07 M |
| Operating Expenses | -35.7 M |
| Operating Income | 35.7 M |
| Other Expenses | 64.8 M |
| Net Income | -29.2 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-34.52%
ROE
-27.15%
ROA
39.63%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Alpha Tau Medical Ltd.
| Net Income | -29.2 M |
| Depreciation & Amortization | 1.07 M |
| Capital Expenditures | -6.4 M |
| Stock-Based Compensation | 7.93 M |
| Change in Working Capital | 2.49 M |
| Others | 9.99 M |
| Free Cash Flow | -24.4 M |
Wall Street Analysts Price Targets
Alpha Tau Medical Ltd.
Wall Street analysts predict an average 1-year price target for DRTS of $7 , with forecasts ranging from a low of $7 to a high of $7 .
DRTS Lowest Price Target
Wall Street Target
7 USD
213.90%
DRTS Average Price Target
Wall Street Target
7 USD
213.90%
DRTS Highest Price Target
Wall Street Target
7 USD
213.90%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Alpha Tau Medical Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference
JERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the Citi 2024 Global Healthcare Conference on December 3rd, 2024 and the Piper Sandler 36th Annual Healthcare Conference on December 5th, 2024.
globenewswire.com
- 3 days ago
Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, announced today that it has been accepted into the prestigious Total Product Life Cycle (TPLC) Advisory Program (“TAP”) Pilot of the U.S. Food and Drug Administration (“FDA”), to accelerate market access to the Alpha DaRT for patients with recurrent glioblastoma multiforme (“GBM”). This acceptance follows the Company's previous receipt of Breakthrough Device Designation from the FDA for this indication, one of two such designations received for the Alpha DaRT, and a pre-requisite for application to the TAP program.
globenewswire.com
- 3 weeks ago
Alpha Tau Treats First Patient with Recurrent Lung Cancer
JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that its first patient with recurrent lung cancer has been treated, in a clinical trial at Hadassah Medical Center in Jerusalem, Israel.
globenewswire.com
- 1 month ago
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population - -Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this patient population -
globenewswire.com
- 1 month ago
Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference
JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present a corporate overview and update at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th, 2024 and in the Sidoti Virtual Investor Conference on September 18-19th, 2024 and will participate in the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference on September 26th, 2024 and the Lytham Partners Fall 2024 Investor Conference on October 1st, 2024.
globenewswire.com
- 2 months ago
Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term safety and efficacy data in multiple hard-to -treat superficial cancers , with an overall response rate of almost 100% in treated le sions , no moderate or severe long-term toxicities noted, and a 2-year local recurrence-free survival was estimated at 77% - - Cash, cash equivalents & deposits balance of $ 74.1 million with runway of at least two years - JERUSALEM, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported second quarter 2024 financial results and provided a corporate update.
globenewswire.com
- 3 months ago
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity.
globenewswire.com
- 4 months ago
Alpha Tau to Present at the Jefferies Global Healthcare Conference
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview and update at the Jefferies Global Healthcare Conference on June 5th, 2024.
globenewswire.com
- 5 months ago
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow -
globenewswire.com
- 5 months ago
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada.
globenewswire.com
- 6 months ago
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone
globenewswire.com
- 6 months ago
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present at the following investor conferences in May 2024.
globenewswire.com
- 6 months ago
8. Profile Summary
Alpha Tau Medical Ltd. DRTS
COUNTRY
IL
INDUSTRY
Biotechnology
MARKET CAP
$ 156 M
Dividend Yield
0.00%
Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Contact
5 Kiryat Hamada Street, Jerusalem, 9777605
https://www.alphatau.com
IPO Date
March 8, 2021
Employees
121
Officers
Mr. Amnon Gat
Chief Operations Officer
Prof. Yona Keisari
Chief Scientific Officer & Member of Scientific Advisory board
Ms. Rebecca Becker
Vice President of legal
Mr. Raphi Levy
Chief Financial Officer
Prof. Itzhak Kelson
Chief Physics Officer & Member of Scientific Advisory Board
Ms. Yael Zeiger
Corporate Controller
Mr. Peter M. Melnyk
Chief Commercial Officer
Dr. Robert B. Den M.D.
Chief Medical Officer & Member of Scientific Advisory Board
Mr. Ronen Segal
Chief Technology Officer
Mr. Uzi Sofer
Chief Executive Officer & Chairman